Orchid Pharma Past Earnings Performance
Past criteria checks 2/6
Orchid Pharma has been growing earnings at an average annual rate of 44%, while the Pharmaceuticals industry saw earnings growing at 14.2% annually. Revenues have been growing at an average rate of 11.5% per year. Orchid Pharma's return on equity is 11.2%, and it has net margins of 15.3%.
Key information
44.0%
Earnings growth rate
-22.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 17.5% |
| Revenue growth rate | 11.5% |
| Return on equity | 11.2% |
| Net Margin | 15.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Orchid Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 8,122 | 1,246 | 703 | 0 |
| 30 Sep 23 | 7,513 | 1,027 | 678 | 0 |
| 30 Jun 23 | 7,178 | 775 | 680 | 0 |
| 31 Mar 23 | 6,659 | 531 | 664 | 0 |
| 31 Dec 22 | 6,341 | -175 | 646 | 0 |
| 30 Sep 22 | 6,357 | -356 | 654 | 0 |
| 30 Jun 22 | 5,982 | -471 | 643 | 0 |
| 31 Mar 22 | 5,596 | -604 | 649 | 0 |
| 31 Dec 21 | 5,010 | -592 | 606 | 0 |
| 30 Sep 21 | 4,424 | -934 | 623 | 0 |
| 30 Jun 21 | 4,232 | -1,009 | 655 | 0 |
| 31 Mar 21 | 4,501 | -952 | 686 | 0 |
| 31 Dec 20 | 4,420 | -1,307 | 882 | 0 |
| 30 Sep 20 | 4,687 | -1,136 | 800 | 0 |
| 30 Jun 20 | 4,918 | -1,153 | 814 | 0 |
| 31 Mar 20 | 4,838 | -697 | 863 | 0 |
| 31 Mar 19 | 6,000 | 694 | 945 | 0 |
| 31 Mar 18 | 6,830 | -3,528 | 984 | 0 |
| 31 Mar 17 | 7,965 | -4,954 | 921 | 0 |
| 31 Mar 16 | 8,734 | -2,791 | 988 | 0 |
| 31 Mar 15 | 11,644 | -1,311 | 1,397 | 0 |
| 30 Sep 13 | 12,985 | -3,720 | 2,638 | 580 |
Quality Earnings: 524372 has a large one-off gain of ₹400.0M impacting its last 12 months of financial results to 31st December, 2023.
Growing Profit Margin: 524372 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 524372 has become profitable over the past 5 years, growing earnings by 44% per year.
Accelerating Growth: 524372 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 524372 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (23.3%).
Return on Equity
High ROE: 524372's Return on Equity (11.2%) is considered low.